Lupin gets US health regulator nod for anti-allergic tablets

Drug firm Lupin has been granted final approval by the United states Food and Drug Administration (USFDA) for antihistamine Desloratadine tablets, used for treating allergies. The approval has been given to Lupin Pharmaceuticals, Lupin's wholly owned US subsidiary for Desloratadine tablets in the strength of 5 mg.

Desloratadine tablets 5 mg are generic version of Clarinex tablets 5 mg of US-based drug major Schering-Plough. According to IMS Health, clarinex tablets have recorded sales of $229 million for this year. The company has filed 132 abbreviated new drug applications for this financial year, of which 45 have been approved by the USFDA.